Zenas BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	44.01	319.74	56.86	67.21
Short-Term Investments	229.27	31.02	-	-
Cash & Short-Term Investments	273.28	350.77	56.86	67.21
Cash Growth	48.58%	516.93%	-15.40%	-
Prepaid Expenses	4.02	3.07	1.65	1.24
Restricted Cash	-	0.09	-	-
Other Current Assets	-	2	1.3	-
Total Current Assets	278.6	355.92	59.8	68.44
Property, Plant & Equipment	1.07	1.19	1.01	1.8
Long-Term Deferred Charges	-	-	1.39	-
Other Long-Term Assets	11.8	12.86	5.97	4.33
Total Assets	293.09	369.97	68.18	74.58
Accounts Payable	7.93	17.14	5.4	5.82
Accrued Expenses	44.52	39.16	17.01	19.44
Current Portion of Leases	0.79	0.79	0.56	0.72
Current Income Taxes Payable	-	0.21	0.3	-
Total Current Liabilities	53.24	57.29	23.26	25.97
Long-Term Debt	-	-	20.3	-
Long-Term Leases	0.22	0.22	0.26	0.81
Total Liabilities	53.46	57.51	43.82	26.78
Common Stock	0	0	-	0
Additional Paid-In Capital	712.9	699.65	4.65	1.03
Retained Earnings	-473.19	-387.39	-230.4	-193.28
Comprehensive Income & Other	-0.09	0.19	0.04	-0.04
Total Common Equity	239.63	312.46	-225.72	-192.29
Shareholders' Equity	239.63	312.46	24.37	47.8
Total Liabilities & Equity	293.09	369.97	68.18	74.58
Total Debt	1.01	1	21.11	1.53
Net Cash (Debt)	272.27	349.76	35.74	65.68
Net Cash Growth	48.44%	878.52%	-45.58%	-
Net Cash Per Share	8.17	26.50	23.34	44.02
Filing Date Shares Outstanding	42.11	41.8	1.58	1.55
Total Common Shares Outstanding	42.09	41.79	1.58	1.55
Working Capital	225.36	298.63	36.55	42.48
Book Value Per Share	5.69	7.48	-143.15	-124.11
Tangible Book Value	239.63	312.46	-225.72	-192.29
Tangible Book Value Per Share	5.69	7.48	-143.15	-124.11

Updated May 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q